Bayer lifts 2026 outlook after strong third quarter

That matters because pharmaceuticals remains Bayer’s main engine for growth while its consumer health and crop science businesses face more uneven demand and pricing pressure. A stronger drug franchise gives the company a cleaner path to earnings growth, better cash generation and more flexibility to keep reducing debt, which has been a central concern since the Monsanto acquisition saddled the group with elevated leverage and legal overhang.

The improved guidance also reflects a broader change in the investment case. Bayer is no longer being judged only on litigation risk and balance-sheet strain, but on whether its pharmaceutical pipeline can offset legacy weakness elsewhere in the portfolio. Nubeqa, a prostate cancer medicine, and Kerendia, used in chronic kidney disease linked to type 2 diabetes, are now doing the heavy lifting. Their performance suggests Bayer can still extract value from its drug portfolio even as older products mature.

Shares reflected that shift. Bayer stock rose more than 7% on the update and has been trading well above its 50-day and 200-day moving averages, with momentum indicators pointing to a strong breakout. On Nov. 4, the shares closed at 15.22 euros, versus 13.95 euros two days earlier, extending a rally that has pushed the stock far above both moving averages and into overbought territory on RSI readings.

The legal backdrop remains relevant, even if it is no longer the sole driver. Bayer’s recent courtroom win in a major Roundup case helped reinforce the market’s view that worst-case litigation risk may be easing, at least for now. That lowers the discount investors had applied to the stock and improves the odds that stronger operating results can translate into a re-rating rather than simply offsetting old liabilities.

For investors, the key question now is whether the pharmaceuticals rebound is sustainable. Bulls will point to the momentum in Nubeqa and Kerendia, the improved outlook and the company’s progress on debt reduction. Bears will argue that Bayer still faces patent cliffs, legal uncertainty and an exposed crop science business that can quickly absorb operating gains. The next test will be whether the drug division can keep compounding growth into 2027 without relying on one-off legal relief or a favorable currency backdrop.